Navigation Links
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
Date:12/21/2007

CALGARY, Dec. 21 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in its Phase Ia/Ib U.K. clinical trial investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN(R) at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The treatment appears to have been well tolerated by the patients and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers.

Interim results were presented at the National Cancer Research Institute conference on October 2, 2007 in Birmingham, U.K. and at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24, 2007.

The primary objective of the trial is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN(R) when administered intratumourally to patients receiving radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The principal investigators for the trial are Dr. Kevin Harrington of the Targeted Therapy Laboratory, Cancer Research UK Centre for Cell and Molecular Biology, The Institute of Cancer Research and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust, London, UK, and Dr. Alan Melcher of the Cancer Research U.K. Clinical Centre at St. James's University Hospital in Leeds. The trial enrolled patients at the Royal Marsden and St. James's Hospitals in the U.K.

About Oncolytics Bi
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Think Drinks are a neuroscience-backed drink regimen developed ... are the first functional focus beverage to give users ... to the temporary fix associated with energy drinks. truBrain ... 2014, with hopes to raise $50,000 over the course ... http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks were designed ...
(Date:7/23/2014)... July 23, 2014  AuraSense Therapeutics, the pioneer ... gene regulatory and immunotherapeutic agents, announced today ... AuraSense Therapeutics, executive leadership team as chief ... Prior to joining AuraSense Therapeutics, Mr. Snyder ... Officer of Cellular Dynamics International Inc., where ...
(Date:7/23/2014)... Shimadzu Scientific Instruments has launched the ... developed jointly with Ajinomoto Co. Inc. Offering simultaneous ... amino acids in nine minutes, drastically enhancing laboratory ... utilizing a fast application-specific column and an LCMS-2020 ... even under conditions with difficult samples that contain ...
(Date:7/23/2014)... 23, 2014 Last year, Formedix ... a leading global provider of data management solutions for ... a leading-edge system for electronic data capture (EDC) and ... design and study execution tools added TrialMaster to its ... anticipated version of Transform for TrialMaster, is being released ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... physics of the perfect pizza toss and will use ... thinner that a human hair. , Mr Daniel (Kuang-Chen) ... Friend and Senior Lecturer Leslie Yeo, videotaped a professional ... Research Laboratory, then calculated how best to describe the ...
... WAYNE, Pa., April 27 Encorium Group, Inc. ... full-service multinational contract research organization (CRO) that provides design, ... registries to many of the world,s leading pharmaceutical companies, ... new business contracts, consisting of both new business contracts ...
... ", or "the Company") (OTC Bulletin Board: SNBP) is ... seven key patents from Company CEO Dr. Lequn Huang ... enhance Sinobiopharma,s ability to execute on its mission of ... for the following:, , ...
Cached Biology Technology:Pizza tossing art unlocks secrets of tiny motors 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:7/23/2014)... health risk warning for Yellowknife and surrounding area because ... fires. In the image taken by the Aqua ... patterns. Fire is an obvious health hazard, but ... so obvious and its effects are insidious. , The ... crop, structure, tires, waste or wood burning) is a ...
(Date:7/23/2014)... , , , , ... , , , , ... extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost ...
(Date:7/23/2014)... 23, 2014 Migratory songbirds are disappearing, and though ... change, loss of habitat, acid rain and light pollution, ... where do these birds go once they leave their ... along the way? , To answer this question, a ... the first ever migratory connectivity map produced for a ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2
... clinical trial, a new drug that selectively blocks ... acute kidney transplant rejection as cyclosporine, the standard ... experimental drug, a co-stimulatory blocker called belatacept (LEA29Y), ... of the toxic side effects associated with standard ...
... and chimpanzees both pass on "traditions" to other members ... feeding behaviour. The findings add to evidence that cultural ... involved killerwhales at Marineland in Niagara Falls in Ontario, ... to catch birds, and passed the strategy on to ...
... mast cells, known to play a central role in ... that can kill these cells by programming them to ... move researchers another step closer to understanding the life ... new treatments for allergy and inflammatory responses in arthritis, ...
Cached Biology News:New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4More animals join the learning circle 2Climate model links higher temperatures to prehistoric extinction 2
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
... for fine-tuning the bombardment conditions for your ... when you are first using the PDS-1000 ... g each of 0.6 micrometer, 1.0 micrometer, ... each of 9 rupture disks, 500 macrocarriers, ...
... Gene Expression (SAGE) is a powerful ... a cost-effective outsourcing solution for sequencing ... Agencourt's SAGE sequencing service provides our ... long Phred20 read lengths (40 SAGE ...
Biology Products: